2024-09-11 - Analysis Report
## JNJ Stock Analysis Report

**Company:** Johnson & Johnson (JNJ)

**Company Overview:**  Johnson & Johnson is a multinational corporation that develops and sells a wide range of healthcare products, including pharmaceuticals, medical devices, and consumer products.

**Performance Analysis:**

1. **Performance vs. S&P 500:**  JNJ's cumulative return of 20.3% is significantly lower than the S&P 500's (VOO) cumulative return of 83.37%. The current divergence is -63.07, indicating that JNJ has underperformed the S&P 500 by 63.07% over the historical period. The relative divergence of 19.85 suggests that JNJ's performance currently sits at the 19.85% percentile in terms of its historical performance compared to the S&P 500.

2. **Recent Price Movement:**
    * **Closing Price:** $166.61
    * **5-Day Moving Average:** $166.1
    * **20-Day Moving Average:** $162.75
    * **60-Day Moving Average:** $155.8

    JNJ's price is currently above all three moving averages, indicating an upward trend in the short to medium term.

3. **Technical Indicators:**
    * **RSI:** 71.46 (Overbought)
    * **PPO:** -0.01 (Slight Sell Signal)
    * **Delta_Previous_Relative_Divergence:** 0.18 (Short-term downtrend)
    * **Expected_Return:** 10.99% (Potential 5-year return on investment)

    The RSI suggests the stock is overbought, implying potential for a short-term correction. The PPO, though slightly negative, doesn't signal a strong sell signal. The recent relative divergence indicates a short-term downtrend, although the expected return suggests potential for long-term growth.

4. **Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ's recent earnings have been relatively stable, though they have been slightly below analyst expectations. 
It's important to note that the 2023-10-27 earnings were reported twice (possibly due to a correction), and we are only considering the most recent report for analysis.

**Overall Analysis:**

JNJ's performance has lagged behind the S&P 500 in the past, but its recent price movement indicates an upward trend. Technical indicators suggest the stock is currently overbought, but the expected return remains positive. While recent earnings have been somewhat below expectations, the company's overall financials remain stable. Investors should monitor the stock closely for potential corrections in the short term, but the long-term outlook for JNJ remains positive due to its strong brand recognition, diverse product portfolio, and solid financial position.